Development of leprosy in a patient with ankylosing spondylitis during the infliximab treatment: Reactivation of a latent infection?

Clinical Rheumatology

Volumn 28, Issue 5, 2009, Pages 615-617

  Vilela Lopes, Roberta ^a   Barros Ohashi, Claudia ^a   Helena Cavaleiro, Luiza ^a   de Britto Pereira Cruz, Rosana ^b   da Veiga, Rossana Ruth Garcia ^b   Fernando Ribeiro Miranda, Mário ^b   Toshimitsu Yoshikawa, Gilberto ^a  

^a Fundação Faculdade Federal de Ciências Médicas de Porto Alegre   (Brazil)

^b FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

Ankylosing spondylitis; Biologic therapy; Infliximab; Leprosy; Mycobacteria

Indexed keywords

CLOFAZIMINE; DAPSONE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RIFAMPICIN; SALAZOSULFAPYRIDINE;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; LEPROMATOUS LEPROSY; MALE; MYCOBACTERIUM LEPRAE; NEURITIS; PRIORITY JOURNAL; SKIN BIOPSY;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOPSY; HUMANS; LEPROSY; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 64449088137     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-009-1140-0     Document Type: Article

References (14)

1. Manadan AM, James N, Block JA (2007) New therapeutic approaches for spondyloarthritis. Curr Opin Rheumatol 19:259-264
2. Tektonidou MG, Skopouli FN (2008) Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: Reactivation of a latent infection? Clin Rheumatol 27:541-542
3. Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD (2008) The use of anti-tumor necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 67:710-712
4. Scollard DM, Joyce MP, Gillis TP (2006) Development of leprosy and type 1 leprosy reactions after treatment with infliximab: A report of 2 cases. Clin Infect Dis 43:19-22
5. Faber WR, Jensema AJ, Goldschmidt WF (2006) Treatment of recurrent erythemanodosum leprosum with infliximab. N Engl J Med 355(7):739
6. da Silva Sobrinho RA, Mathias TA (2008) Prospects for the elimination of leprosy as a public health problem in the state of Paraná, Brazil. Cad Saude Publica 24(2):303-314
7. Kerr-Pontes LRS, Barreto ML, Evangelista CMN, Rodrigues LC, Heukelbach, Feldmeier H (2006) Socioeconomic, environmental, and behavioral risk factors for leprosy in North-east Brazil: Results of a case-control study. Int J Epidemiol 5(4):994-1000
8. Ellerin T, Rubin RH, Weinblatt ME (2003) Infections and anti-tumour necrosis factor alpha therapy. Arthristis Rheum 48:3013-3022
9. Handerson C, Davis JC (2006) Drug insight: Anti-tumor-necrosis-factor therapy for ankylosing spondylitis. Nat Clin Pract Rheumatol 2(4):211-218
10. Clegg DO (2006) Treatment of ankylosing spodylitis. J Rheumatol 35(suppl 78):24-31
11. Furst DE, Breedveld FC, Kalden JR et al (2007) Updated consensus statement on biological agents for the treatment of rheumatic disease, 2007. Ann Rheum Dis 66:2-22
12. Askling J, Dixon W (2008) The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 20:138-144
13. Oberstein EM, Kromo O, Tozman EC (2008) Type I reaction of Hansen's disease with exposure to adalimumab: A case report. Arthritis Rheum 59(7):1040-1043
14. Lockwood DN, Suneetha S (2005) Leprosy: Too complex a disease for a simple elimination paradigm. Bull World Health Organ 83(3):230-235